vTv Therapeutics(US:VTVT)2026-03-10 20:32Revenue Generation - The company has not generated any revenue from drug sales to date, with revenue primarily derived from milestone payments and collaboration agreements [358]. - The company has not generated any revenue from drug product sales and does not expect to until regulatory approval is obtained [386]. Financial Performance - The company reported a net loss attributable to vTv Therapeutics Inc. of $26.974 million for the year ended December 31, 2025, compared to a net loss of $18.462 million in 2024 [370]. - The total operating expenses for the year ended December 31, 2025, were $32.808 million, an increase of $7.611 million from $25.197 million in 2024 [370]. - Net cash used in operating activities for the year ended December 31, 2025, was $25.3 million, a slight decrease of $0.1 million from the previous year [382][383]. - Interest income for the years ended December 31, 2025, and 2024 was $1.9 million and $1.6 million, respectively, related to interest and dividend income from money market accounts [374]. Research and Development - Research and development expenses increased by approximately $6.3 million, or 54.7%, from $11.5 million in 2024 to $17.9 million in 2025, driven by higher spending on cadisegliatin and increased indirect costs [372]. - The company plans to continue incurring significant research and development expenses as it advances the development of cadisegliatin and other drug candidates [362]. - Research and development costs include cash compensation, clinical trials, and regulatory compliance, which are expensed as incurred [398]. Capital and Funding - The company anticipates needing additional capital to fund operations and expects to continue experiencing negative cash flows from operating activities for the foreseeable future [376]. - The company plans to finance operations through cash reserves and future funding activities, including potential equity investments and licensing [387]. - The company entered into a sales agreement with TD Cowen to offer up to $50.0 million in Class A common stock, with $47.5 million remaining available for sale as of December 31, 2025 [380]. - Net cash provided by financing activities increased to $77.4 million in 2025, driven by sales of Units in the 2025 Private Placement for proceeds of $80.0 million [385]. - Future capital requirements will depend on the progress and costs associated with clinical trials for cadisegliatin, as well as regulatory approval timelines [388]. Expenses - General and administrative expenses rose by approximately $1.3 million, or 9.5%, from $13.7 million in 2024 to $14.9 million in 2025, primarily due to increases in share-based expenses and payroll costs [373]. - Significant commercialization expenses are anticipated for product sales, marketing, and distribution once regulatory approval is achieved [386]. Financial Position - As of December 31, 2025, the company had an accumulated deficit of $326.7 million and cash and cash equivalents of $88.9 million [376]. - The company maintains cash and cash equivalents with high credit quality institutions to manage market risk and preserve capital [403]. - The company has no off-balance sheet arrangements as of December 31, 2025 [391].